BioSpace News Archive

NImmune Biopharma will be presented at the American College of Rheumatology’s (ACR) annual meeting. ACR Convergence 2023 will take place from November 10-15, 2023, at the San Diego Convention Center in San Diego, California, with NImmune’s poster presentation to take place on Tuesday, November 14 from 9:00 am – 11:00 am.

TriSalus Life Sciences Inc., (Nasdaq: TLSI), a publicly traded oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

GE HealthCare (Nasdaq: GEHC), is announcing today that President and Chief Executive Officer, Peter Arduini, and Vice President and Chief Financial Officer, Jay Saccaro, will hold a fireside chat from the RSNA 2023 annual meeting on Wednesday, November 29 th at 9:15 am ET/8:15 am CT.

Vivasure Medical® today announced it has enrolled the 100th patient in its PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and efficacy of the Vivasure PerQseal® Closure Device System.

SonALAsense today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to the development program of SONALA-001 in combination with the INSIGHTEC Exablate 4000 Type-2 Device for the treatment of patients with diffuse intrinsic pontine glioma (DIPG).

Modular Medical, Inc. today announced it will be presenting at the Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7, 2023 at the New York Athletic Club in New York City.

Natera, Inc. today announced that it has entered into an agreement with Merck, under which Merck will utilize Natera’s real-world database (RWD) to advance oncology research.

Medicenna Therapeutics Corp. today announced financial results and corporate highlights for the second quarter of fiscal 2024, ended September 30, 2023.

Evoke Pharma, Inc. announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s commercially available and FDA-approved nasal formulation of metoclopramide, GIMOTI.

YS Biopharma Co., Ltd. is pleased to announce that Noble Capital Markets has initiated equity research coverage on the Company with an “Outperform” rating and a 12-month price target of US$5.25 per share.